

Express Mail No. EV170136379US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jiangchun Xu et al.
Application No. : 09/656,668
Filed : September 7, 2000
For : OVARIAN TUMOR SEQUENCES AND METHODS OF
USE THEREFOR

Examiner : Monika B. Sheinberg
Art Unit : 1631
Docket No. : 210121.484C3
Date : September 23, 2002

#22/
Plunkett
9/26/02

DECLARATION OF STEVEN P. FLING Ph.D., UNDER 37 C.F.R. § 1.132

Box RCE
Commissioner for Patents
Washington, D.C. 20231

The undersigned, Dr. Steven P. Fling, hereby declares:

1. I am a Scientist at Corixa Corporation, the assignee of the subject application. The following experiments were carried out under my supervision.

2. I have reviewed the Office Action dated June 17, 2002 and the Advisory Action dated September 3, 2002, in the subject application, including the rejections under 35 U.S.C. §§ 101 and 112, and provide this Declaration for the purpose of providing more evidence to the Examiner that the SEQ ID NO:198, as described in the specification is clearly over-expressed in ovarian tumors relative to normal tissue.

3. Expression analysis of ovarian cancer-associated sequence SEQ ID NO:198 (i.e., or O590S) as performed by Real-Time PCR. Real Time PCR (e.g., Gibson et al., *Genome Research* 6:995-1001, 1996; Heid et al., *Genome Research* 6:986-994, 1996) is a technique that evaluates the level of PCR product accumulation during amplification. This technique permits quantitative evaluation of mRNA levels in multiple samples. Briefly, mRNA was extracted from tumor and normal tissue and

Express Mail No. EV170136379US


cDNA was prepared using standard techniques. Real Time PCR was performed using a Perkin Elmer/Applied Biosystems (Foster City, CA) 7700 Prism instrument. Matching primers and fluorescent probes were designed for O590S (SEQ ID NO:198) using the primer express program provided by Perkin Elmer/Applied Biosystems (Foster City, CA). Optimal concentrations of primers and probes were determined and control (*e.g.*, β -actin) primers and probes were obtained commercially from Perkin Elmer/Applied Biosystems (Foster City, CA). To quantitate the amount of O590S specific mRNA in a sample, a standard curve was generated using a plasmid containing O590S. A standard curve was generated using the Ct values determined in the Real Time PCR, which were related to the initial cDNA concentration used in the assay. Standard dilutions ranging from 10^1 - 10^6 copies of the gene of interest were generally sufficient. In addition, a standard curve was generated for the control sequence. This permits standardization of initial RNA content of a tissue sample to the amount of control for comparison purposes.

Real Time PCR analysis demonstrated that SEQ ID NO:198, clone 57886 or O590S, was shown to be over-expressed in over 65% of ovarian tumor samples tested, 50% of tumor samples derived from SCID mice, and 35% of ovarian tumor cell lines tested, when compared to both normal ovarian tissue, in addition to an extensive panel of normal tissue. Little or no expression was observed in normal esophagus, spinal cord, bladder, colon, liver, PBMC (activated or resting), lung, skin, small intestine, stomach, skeletal muscle, pancreas, dendritic cells, heart, spleen, bone marrow, thyroid, trachea, thymus, bronchia, cerebellum, breast, brain, bone, adrenal gland and salivary gland. Some low level expression was observed in normal kidney, ureter, uterus and peritoneum epithelium, with the expression levels in these normal tissues ranging from approximately 10-fold to 500-fold lower than the levels observed in ovary tumors over-expressing O590S (SEQ ID NO:198).


4. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that

Express Mail No. EV170136379US

willful, false statements, and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.


Steven P. Fling, Ph.D.

Date



C:\NrpPortb\NManage\HELENM308869_1.DOC

MBS 9/26/02
Received 9/26/02 001**SEED**

Intellectual Property Law Group PLLC

701 Fifth Avenue, Suite 6300
Seattle WA 98104-7092 USA
Facsimile: (206) 682-6031
Telephone: (206) 622-4900
www.seedlaw.comHelen P. Mutimer, Ph.D.
helenmu@seedlaw.com

September 26, 2002

Facsimile Transmission4 pages including this page**TO: EXAMINER: Monika Sheinberg**
ART UNIT: 1631
Fax No.: 703-746-5266**RE: U.S. Patent Application No. 09/656,668**
Filed September 7, 2000
Attorney Docket No.: 210121.484C3☒ Urgent ☐ For Review ☐ Please Confirm Receipt ☐ Please Reply ASAP**Comments:****Dear Examiner Sheinberg:**

Attached please find the signed declaration of Dr. Steven P. Fling that was forwarded unsigned to the PTO with Response to Advisory Action and RCE documents September 17, 2002. The original executed declaration will be mailed via Federal Express today as requested.

If you do not receive all pages, please call JUDY DAVIES at (206) 622-4900 or fax our office.

Transmission Information: Date _____ Time _____ By _____

CONFIDENTIALITY NOTICE: The information contained in this facsimile message is legally privileged and/or confidential information intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this facsimile or its content is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile message to us by mail or destroy it without making a copy. Thank you.